What Гайро Treats: Main Uses and Benefits

The primary purpose of Гайро (Ornidazole) is to provide targeted anti-infective support for conditions caused by specific protozoa and anaerobic bacteria, and it is used to address the infectious source associated with acute symptoms. This assists with maintaining functional stability when symptoms are more noticeable.

---

Therapeutic Coverage and Patient Benefit

This medicine is commonly used across conditions presenting with acute episodes of specific parasitic infections such as Amoebiasis and Giardiasis, which often present with severe gastrointestinal distress. It is also applied across domains where additional symptomatic support is needed for genitourinary infections, including Trichomoniasis and Bacterial Vaginosis, alongside specific systemic or localized anaerobic infections like septicemia and peritonitis. It is relevant for addressing the causative pathogen, which may assist with managing the symptomatic episodes that interfere with daily functioning and contributes to easing overall comfort during symptomatic periods.

In general clinical scenarios, the drug is often applied when short-term symptomatic assistance is needed for preventing infection, notably for surgical prophylaxis prior to certain high-risk procedures. This approach supports patients during episodes of heightened discomfort and provides supportive relief.

Quick Fact	Relief for Symptom Categories
Primary Focus	Conditions involving gastrointestinal distress, urogenital inflammation, and systemic fever related to susceptible pathogens.
Key Benefit	Contributes to improved comfort and assists with maintaining functional stability in situations involving susceptible pathogens.

Regulatory References

1. Medsafe New Zealand Consumer Medicine Information

Eligibility Scope

The eligibility for Гайро (Ornidazole) is defined by regulatory documents based on existing medical conditions and physiological state, classifying populations into allowed, restricted, or prohibited groups.

Category	Official Regulatory Status
Populations for whom use is contraindicated	Individuals with hypersensitivity to Ornidazole or any other nitroimidazole derivatives (e.g., metronidazole). Patients with organic central nervous system (CNS) diseases, including epilepsy and multiple sclerosis.
Pregnancy and lactation eligibility	Use is contraindicated during the first trimester of pregnancy. It is not recommended for use during lactation unless deemed absolutely necessary.
Age-related eligibility rules	Use is established in children based on bodyweight. Infants with a body mass under 6 kg are contraindicated for the intravenous formulation.
Condition-specific eligibility rules	Severe Hepatic Impairment: Requires the dosing interval to be doubled due to prolonged elimination. Renal Impairment: No dose adjustment is required, but a supplemental dose is needed after haemodialysis.

Official prescribing information dictates that caution is required for patients with pre-existing CNS disorders; treatment must be discontinued if signs of peripheral neuropathy or confusion occur. Leukocyte counts should be checked in patients with a history of blood disorders.

Interactions with other medicines and products

The interaction profile of Гайро (Ornidazole) describes specific restrictions and pharmacokinetic changes as officially documented in regulatory sources.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance	Official Regulatory Outcome
Cimetidine	May officially prolong the half-life and decrease the plasma clearance of Ornidazole.
Phenobarbital or Phenytoin	May officially reduce the half-life of Ornidazole.
Coumarin-type Oral Anticoagulants	Officially potentiates the effect of the anticoagulant (e.g., Warfarin).
Vecuronium Bromide	Officially prolongs the muscle relaxant effect.
Lithium	May officially increase plasma levels of Lithium.
Fluorouracil	May officially reduce the clearance of Fluorouracil.

---

Mandatory Substance Restrictions

Official regulatory documentation imposes a timing-based restriction regarding alcohol consumption. Alcohol (Ethanol) must not be ingested during the course of treatment with Ornidazole and for a mandatory period of at least 3 days after the medicine has been discontinued.

Regulatory notes also specify that the half-life of Ornidazole is longer in patients with hepatic impairment, a condition that may necessitate modifications to the dosing interval due to altered interaction potential.

How Гайро Works: Mechanism of Action

Гайро (Ornidazole) functions via a mechanism of selective reductive bioactivation, which is limited to susceptible anaerobic pathogens. The mechanism begins when the drug enters the microbe, where specific electron transport proteins (such as ferredoxin) operate in the low-oxygen, low-redox potential environment. These enzymes chemically reduce the drug's 5-nitro group, converting the relatively inert molecule into a highly cytotoxic nitro free radical anion.

These reactive intermediates rapidly attack the pathogen's core genetic material, causing multiple DNA strand breaks and fragmentation. This catastrophic molecular damage immediately halts crucial cellular processes, including DNA replication and nucleic acid synthesis, which ultimately results in the failure of the pathogen's processes. The resulting physiological effect is classified as a protozoacidal and bactericidal end-point. This mechanism is constrained by the presence of oxygen, which prevents the cytotoxic activation cascade.

Administration Scope

The administration of Ornidazole (Гайро) is governed by specific parameters which dictate the routes, dosage, and timing. The medicine is prepared for oral intake via tablets and for intravenous (IV) infusion, allowing for systemic delivery, with the vaginal route being an auxiliary pathway in certain treatment scenarios.

---

Standard Dosing and Frequency

Standard adult oral regimens vary, ranging from a single 1.5 g dose for certain infections to divided daily use of 1 g per day (500 mg twice daily). For systemic IV treatment, an initial loading dose of 0.5 g to 1 g is administered, typically followed by a maintenance dose of 500 mg every 12 hours. Treatment is generally structured as a short-term course, often lasting up to 10 days.

---

Administration Conditions and Adjustments

Proper administration requires adherence to specific conditions. Oral tablets are taken after meals. The IV solution requires prior dilution to a concentration of 5 mg/mL or less and is infused slowly over 15 to 30 minutes. Use-context constraints also include population adjustments: the standard dosing interval is doubled for patients with severe hepatic impairment, and an additional supplementary dose is required for patients undergoing haemodialysis. Pediatric dosing is determined by body weight.

---

Resulting Procedural Structure

The protocol for severe infections often involves sequential therapy, transitioning from the initial IV infusion to the oral tablet form to complete the prescribed course. The overall procedure is defined by these established administration conditions, dosing frequencies, and population-specific rules to standardize its application.

Research evidence / Overview of studies for Гайро (Ornidazole)

This overview summarizes the type of research that has examined Ornidazole, the active ingredient in Гайро, and outlines what is currently known and what still remains under investigation, according to regulatory and scientific sources. The findings describe group patterns and research does not determine whether an individual will respond similarly.

---

Evidence for use in Protozoal Infections

Research has examined laboratory clearance in specific parasitic infections, such as Amoebiasis, Giardiasis, and Trichomoniasis. Studies conducted during periods of increased symptom activity include short-term Randomized Controlled Trials (RCTs) and comparative clinical trials. The primary focus was to measure outcomes related to laboratory clearance, specifically the eradication of the parasite.

Research monitored rates of parasitological clearance reported by the studies. However, much of the core evidence is older, and follow-up durations were limited, meaning long-term effects are not fully established regarding the durability of these outcomes.

---

Evidence for use in Preventing Surgical Infections (Prophylaxis)

The role of Ornidazole in the context of preventing infections was studied for certain high-risk surgical procedures, primarily through Randomized Controlled Trials (RCTs). These studies examined outcomes focused on the incidence rate of post-operative surgical site infections (SSIs).

The trials documented the specific SSI rates reported in the Ornidazole study group compared to the control group during the initial monitoring period. The standard approach often involves the drug being used as part of a combination regimen, which may make its specific contribution less certain. Results apply only to the populations studied.

---

What is Still Uncertain About the Research for Гайро

A review of the evidence landscape indicates several areas where limited information is available: Evidence quality varies across studies, with many findings derived from older trials. Sample sizes were modest in many trials, particularly those focusing on specific subgroups. There is limited information for long-term outcomes and the durability of the effect. Comparative evidence is lacking in some contexts, as many studies focus on comparing Ornidazole to other drugs in the same class rather than comparing it to a non-drug approach. Study results reflect the specific conditions under which they were conducted.

Common questions about Гайро (FAQ)

Q: Can older adults or senior citizens use Гайро?

A: Official documents for the drug class, and related products, suggest that use in older adults may require specific attention. This is primarily because dosing adjustments may be necessary, particularly if a person has reduced kidney function. Any determination regarding use is made based on individual health status and professional guidance.

---

Q: Why do official documents mention potential dizziness with Гайро?

A: Dizziness is a commonly documented neurological adverse reaction that has been observed in studies of this medication. For this reason, official warnings note that the ability to drive or operate machinery may be affected.

---

Q: Is there a lot of research available about the long-term effects of Гайро?

A: Official research summaries state that much of the core evidence available is older and focuses on short-term outcomes. Consequently, the long-term effects and the durability—or lasting effect—of the outcomes following treatment with Ornidazole are not fully established.

---

Q: Can I take pain relievers like ibuprofen or paracetamol with Гайро?

A: Official drug documents list specific interactions with certain other medicines, but they do not provide a universal statement excluding common over-the-counter pain relievers. However, it is recognized that components in the same drug class as some pain relievers have documented potential interactions.

---

Q: Are there specific symptoms that mean I should definitely contact a doctor right away about Гайро?

A: Official warnings regarding rare but serious reactions specify that certain signs are officially recommended to be reported promptly to a healthcare professional. These include symptoms of a severe allergic reaction (such as swelling or a sudden, severe skin rash), seizures (convulsions), or the onset of numbness or tingling (peripheral neuropathy).

---

Q: Does Гайро change the way my mood or personality feels?

A: The drug class to which Ornidazole belongs (nitroimidazoles) has been associated in some official documents with effects on the central nervous system. These documented effects include reports of changes in mental state, such as depression, irritability, or psychosis.

---

Q: Can I take over-the-counter cold and flu medicines while taking Гайро?

A: Official information recognizes the potential for interactions with cold and flu medicines. This is because these products often contain multiple active ingredients that may overlap with the known interaction profile of Ornidazole, such as specific pain-relief components.

---

Q: Why do some people need a blood test while using Гайро?

A: Blood monitoring, specifically checking white blood cell counts, is officially required for patients with a history of blood disorders. Additionally, if a patient’s treatment course is extended beyond the standard short duration, continuous clinical and laboratory monitoring may be necessary.

---

Q: Is Гайро safe for people who have kidney problems?

A: Official documents indicate that no routine dose adjustment is typically required for patients with general kidney impairment. However, a specific supplemental dose is officially required after a patient undergoes a haemodialysis session.

---

Q: Is Гайро safe for people who have liver issues?

A: Official prescribing information advises caution for patients with impaired liver function. In cases of severe hepatic impairment, the standard dosing interval must be officially doubled. The drug has also been associated with rare reports of idiosyncratic liver injury in regulatory documents.

---

Q: Can I take a multivitamin while on Гайро?

A: While there are no specific warnings against multivitamins listed in the official product information, general regulatory information advises that potential interactions with supplements are generally considered during treatment. This is especially true for products containing high amounts of minerals or other active ingredients.

---

Q: Are there specific herbal supplements that interact badly with Гайро?

A: Specific herbal interactions are generally not listed in official documentation for the drug. However, caution is advised, particularly with any liquid remedies or supplements that may contain components, such as alcohol, which is restricted during the course of treatment.

---

Q: Can teenagers or children use Гайро for specific conditions?

A: Official documents state that the use of Ornidazole is established for children and is determined based on body weight. Some therapeutic uses for the drug class are specifically approved for children aged 3 years and older for certain protozoal infections.

Ornidazole (Гайро) must be stored at conditions that do not allow the temperature to exceed 30 C.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at a temperature not exceeding 30 C.
Protection	Keep in the original container to protect from light and moisture.
Handling	Must be kept out of reach of children.
Packaging	Keep tablets in the blister pack until the time of use.

Official documents strictly require that the product be kept away from heat and dampness, and stored in the original packaging to preserve its stability until the expiry date.

Disposal

Unused or expired Ornidazole should not be disposed of via the sink, toilet, or household waste. Any remaining product must be discarded in strict accordance with local regulations for pharmaceutical waste, often requiring return to a pharmacy or an approved collection program.